Navigation Links
WARF signs license agreement with Pfizer for human embryonic stem cells
Date:5/6/2009

MADISON Pfizer Inc., a major biopharmaceutical company, and the Wisconsin Alumni Research Foundation (WARF), the private, nonprofit patenting and licensing organization for the University of Wisconsin-Madison, announced May 5 that they have signed a license for human embryonic stem (hES) cell patents for the development of new drug therapies.

The WARF license provides Pfizer the rights to work with hES cells for drug research and discovery. Securing appropriate licenses, in an area as broad and rapidly moving as regenerative medicine, helps ensure rapid and efficient utilization of the many existing discoveries and inventions in this field and allows for the efficient transfer of information for development of future inventions.

"Our license with WARF provides us with information and materials that will allow us to use their cell lines to explore a whole new range of therapies," says Ruth McKernan, chief scientific officer of Pfizer Regenerative Medicine. "Stem cells can be used to create specialized human tissue. Our scientists will determine how new medicines may be able to improve the way stem cells regenerate damaged tissues. We will be optimizing the production of cells that could, one day, be used for therapeutic purposes."

"Pfizer's stem-cell R&D goal is three fold: to use human cells as tools in our drug discovery efforts, to improve the safety of new treatments and, most importantly, to move towards cell therapy," says McKernan. "The benefit to public health could be tremendous as we pursue our discoveries to advance the treatment of debilitating diseases."

"We are pleased to enter into this licensing agreement with Pfizer," said Carl E. Gulbrandsen, managing director of WARF. "Pfizer's access to this key intellectual property may have far-reaching benefits for both public health and Wisconsin's growing biotechnology industry."

As advances in health care help people live longer, the need for new medicines
'/>"/>

Contact: Janet Kelly
jkelly@warf.org
608-890-1491
University of Wisconsin-Madison
Source:Eurekalert

1

GOOD

Page: 1 2

Related biology news :

1. Unifying the animate and the inanimate designs of nature
2. Ben-Gurion University of the Negev signs collaborative contract with Bayer CropScience
3. UK robot sub searches for signs of melting 60 km into an Antarctic ice shelf cavity
4. La Jolla Institute signs exclusive license agreement with Medimmune on major asthma discovery
5. Engineering technology pinpoints earliest signs of animal life
6. University of Miami engineer designs stretchable electronics with a twist
7. bioMETRX, Inc. Signs Deal To Acquire Controlling Interest in Biometric Solutions, LLC
8. Umbilical cord blood cell therapy may reduce signs and symptoms of Alzheimers disease
9. Great Ape Trust signs agreement with Universitas Nasional in Jakarta
10. Titanium Group Signs Letter of Intent to Acquire Multimilion Dollar Medical Software Company and Its Existing Sales Network
11. Titanium Group Signs Letter of Intent to Acquire Multimilion Dollar Medical Software Company and Its Existing Sales Network
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)The 30-year record low in Antarctic snowmelt that occurred during the 2008-09 austral summer was likely due to concurrent strong positive phases for two main climate drivers, ENSO (El Nio - Southern O
(Date:12/2/2009)PHILADELPHIA Less acculturated Latino men have a more difficult time quitting smoking than those who are more acculturated to U.S. culture, but acculturation has no affect on Latinas odds of quitting
(Date:12/2/2009)PHILADELPHIA Cigarette smoking and alcohol consumption before head and neck cancer diagnosis strongly predicts the patient,s future risk of death, according to published studies. Now, results of a ne
Breaking Biology News(10 mins):CCNY professor foresees rising Antarctic snowmelt 2Acculturation affects smoking cessation success among Latinos 2Head and neck cancer survivors who use alcohol and cigarettes have increased death risk 259 percent support Massachusetts Landmark 2006 health reform law 58399 159 percent support Massachusetts Landmark 2006 health reform law 58399 259 percent support Massachusetts Landmark 2006 health reform law 58399 3Excellence in Paediatrics conference line up includes WHO and CDC pandemic speakers 10130 1Excellence in Paediatrics conference line up includes WHO and CDC pandemic speakers 10130 2Getting down to details 10125 1Getting down to details 10125 2
..., Fla. Older, active people who have a drink or t...k, according to a report today from a University o...s on Alcohol and Drugs . , Although people 50 or ...how younger people did, they performed worse on sp...ol and did not always realize when they were impai...
...identified seven new species of bamboo coral disco...of the Papahānaumokuākea Marine National...rely new genera, a remarkable feat given the broad...ajor category in the classification of organisms, ...ists expect to identify more new species as analys...
... largest research project into children,s health a... as obesity, obesity-related diseases and learning...ed by Professor Arne Astrup, is based at LIFE - Fa... and will focus on a new eating concept, termed th...d products. , Overweight has been estimated to aff...
Other Biology News:After a few drinks, older adults more impaired than they think 2After a few drinks, older adults more impaired than they think 3New deep-sea coral discovered on NOAA-supported mission 2Enhanced quality of 'LIFE' through Nordic food 2
(Date:12/2/2009)JERUSALEM, Israel, December 2 Gamida Cell announced today,a feasibility study evaluating the preclinical (animal study) safety and,efficacy of a gene therapy product which combines technology from We
(Date:12/2/2009)NANJING, China, Dec. 2 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group,("Simcere" or the "Company") (NYSE: SCR ), a leading pharmaceutical company,specializing in the development, manufacturing, a
(Date:12/2/2009)The Scientist, a leading scientific magazine covering the life sciences, ranked Photometrics’ Evolve “Intelligent” EMCCD camera fourth among the publication’s “Top 10 Inn
(Date:12/1/2009)INCLINE VILLAGE, Nev., Dec. 1 PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI ) today announced revenue guidance for the fourth quarter ended December 31, 2009 of approximately $57 million, as compared with
Breaking Biology Technology:Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 2Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 3Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 2Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 3The Scientist Names Photometrics' Evolve EMCCD Camera One of the “Top 10 Innovations” of 2009 2The Scientist Names Photometrics' Evolve EMCCD Camera One of the “Top 10 Innovations” of 2009 3PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 2PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 3
...asdaq: TELK ) today announced top-line results fr...yta (canfosfamide HCL) in combination with,pegylat... second-line,therapy in platinum refractory, prima...ant ovarian cancer (definitions of platinum status...) basis for the 125 enrolled patients, the,median ...
...nces Cash Position -, HOPKINTON, Mass., Oct. 29 ...ading provider of tools and services for,drug disc...that it has,reached an agreement to sell its Pharm...duct line to SOTAX Corporation in a transaction va...ct line consists of products used,for drug content...
...me Per Share, SAN JOSE, Calif., Oct. 29 VNUS(R) ...ding provider of medical devices,for the minimally...nced its,financial results for the third quarter e...ird quarter of 2008 increased 32% to $23.1,million... of 2007. Net,revenues for the third quarter of 20...
Other Biology Technology:Telik Announces Top-Line Results From Assist-5 Trial of Telcyta(R) in Combination With Pegylated Liposomal Doxorubicin in Platinum Refractory and Resistant Ovarian Cancer 2Telik Announces Top-Line Results From Assist-5 Trial of Telcyta(R) in Combination With Pegylated Liposomal Doxorubicin in Platinum Refractory and Resistant Ovarian Cancer 3Telik Announces Top-Line Results From Assist-5 Trial of Telcyta(R) in Combination With Pegylated Liposomal Doxorubicin in Platinum Refractory and Resistant Ovarian Cancer 4Caliper Enters Agreement to Divest Non-Core Pharmaceutical Development & Quality Analysis Product Line 2Caliper Enters Agreement to Divest Non-Core Pharmaceutical Development & Quality Analysis Product Line 3VNUS Medical Technologies Reports Third-Quarter 2008 Results: 25% Growth in Net Product Revenues and 29% Growth in Unit Sales Over Third Quarter 2007 2VNUS Medical Technologies Reports Third-Quarter 2008 Results: 25% Growth in Net Product Revenues and 29% Growth in Unit Sales Over Third Quarter 2007 3VNUS Medical Technologies Reports Third-Quarter 2008 Results: 25% Growth in Net Product Revenues and 29% Growth in Unit Sales Over Third Quarter 2007 4VNUS Medical Technologies Reports Third-Quarter 2008 Results: 25% Growth in Net Product Revenues and 29% Growth in Unit Sales Over Third Quarter 2007 5VNUS Medical Technologies Reports Third-Quarter 2008 Results: 25% Growth in Net Product Revenues and 29% Growth in Unit Sales Over Third Quarter 2007 6VNUS Medical Technologies Reports Third-Quarter 2008 Results: 25% Growth in Net Product Revenues and 29% Growth in Unit Sales Over Third Quarter 2007 7VNUS Medical Technologies Reports Third-Quarter 2008 Results: 25% Growth in Net Product Revenues and 29% Growth in Unit Sales Over Third Quarter 2007 8VNUS Medical Technologies Reports Third-Quarter 2008 Results: 25% Growth in Net Product Revenues and 29% Growth in Unit Sales Over Third Quarter 2007 9VNUS Medical Technologies Reports Third-Quarter 2008 Results: 25% Growth in Net Product Revenues and 29% Growth in Unit Sales Over Third Quarter 2007 10
DNA Polymerase I Large (Klenow) Fragment from New England Biolabs
T4 DNA Ligase (HC) from Invitrogen
Rat Anti-STENOTROPHOMONAS MALTOPHILIA Polyclonal Antibody, Unconjugated from AbD Serotec
... upgrade for Shimadzu Phoretix 2D, Expression and ...stical tools for comparative gel analysis studies ...Data base add on component Oracle data base plug...software). Supports advanced statistical tool se...
Biology Products: